A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Hoffmann-La Roche
Hoffmann-La Roche
Royal Marsden NHS Foundation Trust
Hoffmann-La Roche
University of Kansas Medical Center
University of Miami
Massachusetts General Hospital
H. Lee Moffitt Cancer Center and Research Institute
Novartis
Northwestern University
Novartis
MedSIR
Borstkanker Onderzoek Groep
Karolinska University Hospital
UNICANCER
SOLTI Breast Cancer Research Group
Korea University Guro Hospital
Fondazione Sandro Pitigliani
M.D. Anderson Cancer Center
Columbia University
Novartis
University Hospital, Akershus
University of Ulm
National Taiwan University Hospital
Novartis
SOLTI Breast Cancer Research Group
Novartis
Novartis